The Effect of Sorafenib on Portal Pressure
Completed · Phase 2 · Has a placebo group
Conditions studied: Clinically Significant Portal Hypertension
In brief
Sorafenib is approved by the US FDA for the treatment of unresectable (can not operate) liver cancer and for renal cell carcinoma. Sorafenib is a drug that inhibits the growth of cancer cells and prevents the formation of new blood vessels that would otherwise help the cancer spread. Studies in experimental animals have shown that sorafenib may also lower portal vein pressure (the pressure of the blood passing from the intestine through the liver.) This study seeks to determine if sorafenib lowers the blood pressure in liver blood vessels (portal vein pressure) in patients with cirrhosis who have high portal vein pressure. The study will also obtain information whether sorafenib is safe in this patient population. Half of the patients will be given sorafenib and half will be given a placebo (a pill without any medicine in it.) This allows a comparison of the reactions of people who take sorafenib to those who do not.
Key facts
- Study ID
- NCT01714609
- Run by
- Yale University
- People needed
- 10
- Starts
- 2011-08-01
- Expected to finish
- 2014-09-01
- Last updated by the study team
- 2020-12-29
Who can join
Age: 20 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Yale Cancer Center — New Haven, Connecticut, United States
- VA Medical Center West Haven — West Haven, Connecticut, United States
- Brigham & Womens — Boston, Massachusetts, United States
- New York University Langone Medical Center — New York, New York, United States
- University of Pennsylvania School of Medicine — Philadelphia, Pennsylvania, United States
- The University of Texas Health Science Center at Houston — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.